Following the discovery of HIV as a causative agent of AIDS, the expectation was to rapidly
develop a vaccine; but thirty years later, we still do not have a licensed vaccine. Progress …

The use of cancer vaccines is considered a promising therapeutic strategy in clinical
oncology, which is achieved by stimulating antitumor immunity with tumor antigens delivered …

As the global elderly population grows, it is socioeconomically and medically critical to
provide diverse and effective means of mitigating the impact of aging on human health …

Viral vectors can generate high levels of recombinant protein expression providing the basis
for modern vaccine development. A large number of different viral vector expression systems …

The current therapeutic antibody market in the US consists of 100 antibody-based products
and their market value is expected to explode beyond $300 billion by 2025. These therapies …

The liver is a key organ for metabolism, protein synthesis, detoxification, and endocrine
function, and among liver diseases, including hepatitis, cirrhosis, malignant tumors, and …

Viral vectors have emerged as powerful tools for delivering and expressing foreign genes,
playing a pivotal role in gene therapy. Among these vectors, cytomegalovirus (CMV) stands …

Viral vector vaccine represents one of the important research directions of novel vaccines.
Viral vectors can efficiently deliver foreign genes and drive robust transgene expression in …

Older adults often show signs of impaired CD8+ T‐cell immunity, reflected by weaker
responses against new infections and vaccinations, and decreased protection against …

The oncogenicity of the human cytomegalovirus (CMV) is currently being widely debated.
Most recently, mounting clinical evidence suggests an anti-cancer effect via CMV-induced T …